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ETHICAL ISSUES IN HEALTH CARE SECTOR IN INDIA
Chirantan CHATTERJEE and Vasanthi SRINIVASANHealth care institutions globally are facing
challenges in balancing issues around
ethics, economic efficiency, and access
while organising for and delivering services.
In the Indian context, where health
indicators are poor, the issue of ethics
becomes more complex and requires
a nuanced understanding and appreciation
of the context.
In its first part, this round table article
provides an overview of the field of ethics in
health care, the health care sector in India
and its facilities, the key institutional
actors, and finally, the key ethical issues
concerning the different players in health
care, these being the physician, the bio-
pharmaceutical industry, and the chemist.
In the overview of the Indian health care
sector, the points to note are that health
indicators have consistently lagged behind
economic development and that public
expenditure on health is only about 1.1% of
GDP. The majority of Indians trust and
utilise private health care despite the fact
that cost of treatment is significantly higher
than in public facilities. Further a large part
of their expenditure is out-of-pocket and
not accommodated by insurance providers.
Finally, the inadequate penetration of
insurance only means that access to quality
health care is a luxury for a large section of
the population. Moreover, the far-from-
adequate health facilities will be tested
further, given the changing trends in the
disease patterns, changing demographics,increasing urbanisation, and increased
lifespan.
In the second part, the article recounts the
discussion on the many issues associated
with health care by a panel of international
and domestic experts, which includes
representatives from consulting and not-
for-profit institutions, the pharmaceutical
industry, and a physician.
Dr Richard Manning, Partner, Bates White,
an economics consulting firm based in
Washington DC, underlines the issue of
ethics and efficiency pointing out the
overlap between the search for economic
efficiency and the betterment of mankind.
The key two issues in ethics in the context
of health care markets, according to him,
are pricing and marketing. Ethical issues in
pricing cluster around the poles of providing
access to existing medicines for those that
cannot pay and maintaining the incentive to
continue to develop medicines that address
unmet needs. He proposes the idea of
differential pricing through partnerships
among private companies, NGOs, and
governments as a policy lever in contexts
like India. While acknowledging that the
ethical challenge in marketing
pharmaceuticals might be to consider the
incentives facing the physician, he points to
the potential of marketing activities as
a source of information to help people make
economic choices.
Mr. Rijit Sengupta, Director, Consumer
Unity and Trust Society (CUTS)International, emphasises the roles of co-
regulation and self-regulation in
regulating healthcare markets and
businesses, and of voluntary guidelines
such as the National Voluntary Guidelines
(NVG) on Social, Environmental, Economic
Responsibilities of Business. Emphasising
that ethics in health care cannot be seen
in isolation of ethics in society, Mr. Deepak
Sapra, Senior Director (Business
Development and Portfolio), Dr. Reddy’s
Laboratories, builds on several issues
raised by the previous speakers, in
particular the role of pricing, drug
discovery, pharmaceutical research and
clinical trials and the vexed question of
“influencing” doctors and other health
care service providers.
Dr Ravikumar Banda, Founder and MD,
Xycton Diagnostics, highlights the physician-
centricity of health care markets, more so
in contexts like India, and the ethical
questions they pose to ordinary citizens as
well as key nodal bodies such as the Medical
Council of India (MCI) and the Indian
Medical Association (IMA). He raises key
questions on IPR management and
commercialisation of products, and the
point of trust in the success of
publiceprivate partnership. He also brings
out the pivotal role of the Central Drug
Controller General of India in installing
formal regulatory systems to promote
ethical behaviour in Indian health care
markets.
